Our recent results in dietary obese mice demonstrated that rosiglitazone and n-3 LC-PUFA, both compounds administered at a relatively low dose, exerted additive effects in prevention and reversal of dyslipidaemia, low-grade inflammation of adipose tissue, and insulin resistance, reflecting the induction of adiponectin and synergistic improvement in muscle insulin sensitivity [21]. Here, ADIPOQ is linked to inherited lipid metabolism disorder.